肝衰竭并发肝肾综合征临床诊治进展

doi:10.3969/j.issn.1672-5069.2014.02.025

Abstract

Abstract: Hepatorenal syndrome（HRS） is one of serious complications of severe liver diseases including liver failure， decompensated cirrhosis and liver cancer. Although the diagnostic criteria for HRS has been defined clearly， the specific diagnostic indicators are lack in clinical practice. HRS is just a clinical exclusion diagnosis. Once the symptom of significant reduction in the amount of urine with increased serum creatinine levels suddenly appears，it might be the early signs of HRS. As respect to the treatment of HRS，combination of vasoconstrictors and albumin，TIPS，CRRT and MARS could improve renal function， mainly serving as a bridge for liver transplantation. So far，liver transplantation is the most effective treatment for HRS.

Key words: Hepatorenal syndrome, Pre-renal azotemia, Acute tubular necrosis, Diagnosis

Li Jinge, Nie Qinghe.. Progress in clinical diagnosis and treatment of patients with liver failure and hepatorenal syndrome[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 198-201.

References

[1] 聂青和.肝肾综合征诊断及治疗进展.实用临床医药杂志，2007，11（3）：10-12.
[2] Pillebout E. Hepatorenal syndrome. Nephrol Ther，2013，[Epub ahead of print].
[3] Egerod Israelsen M，Gluud LL，Bendtsen F，et al. Hepatorenal syndrome:diagnosis，treatment and prevention. Ugeskr Laeger，2013，175（22）:1562-1566.
[4] 聂青和. 重型肝炎综合治疗进展的临床教学实践及体会.实用肝脏病杂志，2006，9（2）:104-106.
[5] Salerno F，Gerbes A，Ginès P，et al. Diagnosis，prevention and treatment of hepatorenal syndrome in cirrhosis.Gut，2007，56（9）:1310-1318.
[6] 聂青和. 肝衰竭实验室检测临床价值及新指标评价.临床肝胆病杂志，2013，29（9）：666-669.
[7] Lameire NH，Bagga A，Cruz D，et al. Acute kidney injury:an increasing global concern.Lancet，2013，382（9887）:170-179.
[8] Belcher JM，Sanyal AJ，Peixoto AJ，et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology，2013，[Epub ahead of print]
[9] Gueutin V，Meftah A，Desbuissons G，et al. Hepatorenal syndrome:Focus. Nephrol Ther，2013，9（7）:471-480.
[10] Fabrizi F，Aghemo A，Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res，2013，37（6）:588-601.
[11] Blokhina NV，Pasechnik IN.The modern possibilities of the hepato-renal syndrome treatment. Khirurgiia（Mosk），2013，（8）:81-85.
[12] 高禄化，聂青和. 肝衰竭继发感染临床进展. 肝脏，2013；18（1）：61-62.
[13] 聂青和，罗新栋. 肝肾综合征药物治疗及评价. 药品评价，2007，4（4）:276-278，291.
[14] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites，spontaneous bacterial peritonitis，and hepatorenal syndrome in cirrhosis. J Hepatol，2010，53（3）:397-417.
[15] Piano S，Morando F，Fasolato S，et al. Continuous recurrence of type I hepatorenal syndrome and long-term treatment with terlipressin and albumin:a new exception to MELD score in the allocation system to liver transplantation J Hepatol，2011，55:491-496.
[16] Gluud LL，Christensen K，Christensen E，et al. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev，2012，12:CD005162.
[17] Solà E，Cárdenas A，Ginès P.Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Curr Opin Organ Transplant，2013，18（3）:265-270.
[18] Huscsak G，Kaisers UX，Laudi S.Hepatorenal syndrome. Anaesthesist，2013，62 （7）:571-582.
[19] Alessandria C，Debernardi-Venon W，Carello M，et a1.Midodrine in the prevention of hepatorenal syndrome type 2 recurrence:a case-control study. Dig Liver Dis，2009，41（4）：298-302.
[20] 王建军. 奥曲肽联合白蛋白治疗肝肾综合征的临床研究.中国现代药物应用，2013，7（17）:7-8.
[21] Tavakkoli H，Yazdanpanah K，Mansourian M. Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med，2012，3（11）:764-769.
[22] 李梦东，聂青和. 肝衰竭的研究现状与展望. 实用肝脏病杂志，2013，16（1）:9-11.
[23] Wong F，Moore K，Dingemanse J，et a1. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology，2008，47（1）:160-168.
[24] Cetinkaya A，Kantarceken B，Bulbuloglu E，et al. The effects of L-carnitine and N-acetylcysteine on carbontetrachloride induced acute liver damage in rats. Bratisl Lek Listy，2013，114（12）:682-688.
[25] Izzedine H，Kheder-Elfekih R，Deray G，et al. Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome. J Hepatol，2009，50（5）:1055-1056.
[26] Kiser TH，Maclaren R，Fish DN，et al. Treatment of hepatorenal syndrome. Pharmaeotherapy，2009，29（10）:1196-1211.
[27] Lata J. Hepatorenal syndrome. World J Gastroenterol，2012，18（36）:4978-4984.
[28] Angeli P，Gines P. Hepatorenal syndrome，MELD score and liver transplantation:An evolving issue with relevant implications for clinical practice. J Hepatol，2012，57（5）:1135-1140.
[29] Kanazawa H，Sakamoto S，Fukuda A，et al. Living-donor liver transplantation with hyperreduced left lateral segment grafts:a single-center experience. Transplatation，2013，95（5）:750-754.
[30] Moller S，Aagaard NK，Schmidt L，et al. Treatment of the hepatorenal syndrome and hyponatremia in cirrhosis-part II. Dan Med J，2012，59（1）:C4372.
[31] Sourianarayanane A，Raina R，Garg G，et al. Management and outcome in hepatorenal syndrome:need for renal replacement therapy in non-transplanted patients.Int Urol Nephrol，2013，[Epub ahead of print].
[32] P cze B，Fazakas J，Zádori G，et al. MARS therapy，the bridging to liver retransplantation-Three cases from the Hungarian liver transplant program. Interv Med Appl Sci，2013，5（2）:70-75.
[33] Martin R ssle.TIPS: 25 years later. J Hepatol，2012，59（5）:1081-1093.
[34] 聂青和. 肝衰竭综合治疗进展.实用肝脏病杂志，2013；16（1）:17-19.
[35] 聂青和.肝硬化慢性肝衰竭临床治疗实践. 中国实用内科杂志， 2013，33（9）:698-701.

Progress in clinical diagnosis and treatment of patients with liver failure and hepatorenal syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[6]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[7]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[8]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[9]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[10]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[11]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[12]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[13]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[14]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[15]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.